A randomized phase iii protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916)

Prognostic factors affecting the outcome of brain metastases from breast cancer

“…The RTOG has evaluated a number of different radiation fractionation schemes, but median survival seems independent of the dose and schedule [5,16,26,37]. In our study, total dose of WBRT is not a statistically significant predictor of overall survival.…”

Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients

“…The rationale for WBRT was to treat the symptomatic BMs, but also to eliminate any microscopic tumor elsewhere in the brain. Multiple RTOG trials (14)(15)(16)(17) from the 1970s to the 1990s have intensively studied WBRT for BMs. However, no difference in overall survival was observed among the various fractionation schemes studied (18).…”

The pathogenesis and treatment of brain metastases: a comprehensive review

“…Finally, hyperfractioned radiotherapy [37] and radiation sensitizers [38] have failed to demonstrate an improvement in overall survival compared with a standard regimen. However, two recent studies [39,40], demonstrated that patients with lung cancer receiving WBRT with motexafin gadolinium (MGd) had a better time to neurologic and neurocognitive progression than patients receiving WBRT alone.…”